Portal de Periódicos da CAPES

Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy

1994; Wiley; Volume: 73; Issue: 10 Linguagem: Inglês

10.1002/1097-0142(19940515)73

1097-0142

Barbara A. Murphy, Robert J. Motzer, Madhu Mazumdar, Vaia Vlamis, Jerome S. Nisselbaum, Dean F. Bajorin, George J. Bosl,

Neuroblastoma Research and Treatments

CancerVolume 73, Issue 10 p. 2520-2526 ArticleFree Access Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy Barbara A. Murphy M.D., Barbara A. Murphy M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorRobert J. Motzer M.D., Corresponding Author Robert J. Motzer M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkMemorial Sloan-Kettering Cancer Center, 1275 York Avenue, G906, New York, NY 10021===Search for more papers by this authorMadhu Mazumdar Ph.D., Madhu Mazumdar Ph.D. Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorVaia Vlamis M.A., Vaia Vlamis M.A. Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorJerome Nisselbaum Ph.D., Jerome Nisselbaum Ph.D. Department of Clinical Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorDean Bajorin M.D., Dean Bajorin M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorGeorge J. Bosl M.D., George J. Bosl M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this author Barbara A. Murphy M.D., Barbara A. Murphy M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorRobert J. Motzer M.D., Corresponding Author Robert J. Motzer M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkMemorial Sloan-Kettering Cancer Center, 1275 York Avenue, G906, New York, NY 10021===Search for more papers by this authorMadhu Mazumdar Ph.D., Madhu Mazumdar Ph.D. Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorVaia Vlamis M.A., Vaia Vlamis M.A. Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorJerome Nisselbaum Ph.D., Jerome Nisselbaum Ph.D. Department of Clinical Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorDean Bajorin M.D., Dean Bajorin M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this authorGeorge J. Bosl M.D., George J. Bosl M.D. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New YorkSearch for more papers by this author First published: 15 May 1994 https://doi.org/10.1002/1097-0142(19940515)73:10 3.0.CO;2-RCitations: 60AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Background. Serum tumor marker regression (alpha-fetoprotein [AFP] and human chorionic gonadotrophin [hCG]) was studied in patients treated with ifosfamide-based chemotherapy for cisplatin-resistant germ cell tumors (GCT) to investigate the role of marker regression as a predictor of treatment outcome. Methods. Fifty-four patients treated with cisplatin and ifosfamide-containing therapy were the subject of this retrospective analysis. The serum tumor marker half-life (T1/2) for the first two cycles of therapy was calculated for each patient using all marker values Day 7 through the end of the second treatment cycle. A calculated T1/2 for hCG of less than or equal to 3 days or a calculated T1/2 for AFP of less than or equal to 7 days was defined as appropriate marker regression; any T1/2 greater than these values was considered prolonged. A variable designated “marker decline” was defined to indicate whether the serum tumor marker half-life of AFP and/or hCG was satisfactory or unsatisfactory for each individual patient. Both univariate and multivariate analyses were conducted to investigate “marker decline” as a predictor for response, event-free survival (time to death or relapse), and overall survival. Results. Satisfactory marker decline predicted an improved event-free survival and overall survival. The median event-free survival for patients with an unsatisfactory marker decline was 5.8 months versus 20.7 months for patients with a satisfactory marker decline. Survival for patients with an unsatisfactory marker decline was 6.3 months versus 20.7 months for those patients with a satisfactory marker decline. Further evaluation demonstrated that hCG decline was a stronger predictor for improved survival than AFP decline. A multivariate analysis performed on selected clinical variables using a Cox regression model demonstrated that marker decline, pre-treatment hCG, and primary site were independent predictors for event-free and overall survival. Conclusions. The rate of serum AFP and/or hCG decline during the first two cycles of therapy was predictive for event-free and overall survival in GCT patients treated with ifosfamide-based salvage therapy. Those patients with an appropriate serum tumor marker decline had a longer event-free and overall survival. When evaluated separately, the rate of hCG decline was more predictive of treatment outcome than decline of AFP. The rate of serum tumor marker regression during the first two cycles of therapy is a clinically useful tool in assessing treatment outcome at an early point in therapy and may thereby identify patients who could benefit from a change to more intensive therapy. References 1 Bosl GJ, Gluckman R, Geller NL, Golbey RB, Whitmore W, Herr H, et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 1986; 4: 1493– 9. 2 Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435– 40. 3 Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E, Herr H, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990; 66: 2476– 81. 4 Einhorn LH, Weathers T, Loehrer P, Nichols C. Second line chemotherapy with vinblastine, ifosfamide, and cisplatin after initial chemotherapy with cisplatin, VP-16 and bleomycin (PVP16B) in disseminated germ cell tumors (GCT): long term follow-up [abstract]. Proc Amer Soc Clin Oncol 1992; 11: 196. 5 Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 1991; 9: 1549– 55. 6 Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst 1992; 84: 1703– 9. 7 Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorm LH, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124– 8. 8 Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 1992; 69: 550– 6. 9 Blijham G, Spitzer G, Litman J, Zander AR, Verma DS, Vellekoop, et al. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer 1989; 17: 932– 9. 10 Nichols CR, Tricot G, Williams SD, Van Besien K, Loehrer PJ, Roth BJ, et al. Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932– 9. 11 Bajorin DF, Bosl GJ. The use of serum tumor markers in the prognosis and treatment of germ cell tumors. PPO Updates 1992; 6: 1– 11. 12 Droz JP, Kramar A, Rey A. Prognostic factors in metastatic disease. Semin Oncol 1992; 19: 181– 9. 13 Shargel L, Yu A. Applied Biopharmaceutical Pharmacokinetics. 2nd ed. Norwalk: Appleton-Century-Crofts, 1985: 17– 21. 14 Jacobsen GK, Talerman A. Atlas of Germ Cell Tumors. Copenhagen: Munksgaard, 1989: 20– 1. 15 Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990; 50: 5904– 10. 16 Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ. Acute changes in alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 1982; 42: 4855– 61. 17 Picozzi VJ, Freiha FS, Hannigan JF, Torti FM. Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma. Ann Intern Med; 1984; 100: 183– 6. 18 Motzer RJ, Gulati SC, Mazumdar M. Phase II trial of VAB-6 + high dose carboplatin + etoposide (HD C + E) with autologous bone marrow transplantation (AUBMT) for poor risk germ cell tumor (GCT) patients (PTS) [abstract]. Proc Amer Soc Clin Oncol 1993; 12: 233. 19 Motzer RJ, Bajorin DF, Weisen S, Bosl GJ. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience [supplement]. Semin Oncol 1992; 19: 8– 12. 20 Vaitukaitis JL, Braunstein GD, Ross GT. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol 1972; 113: 751– 8. 21 Horwich A, Peckham MJ. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cance Treat Rpt 1986; 70: 1329– 31. 22 Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE. Marker half-life analysis as a prognostic tool on testicular cancer. J Urol 1981; 128: 708– 11. 23 Pocock SJ. Clinical trials: A practical approach. New York: John Wiley and Sons, 1983. 24 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations JASA 1958; 53: 457– 81. 25 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo Rep 1966; 50: 163– 70. 26 Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Currie V, et al. An analysis of the effect of dose intensity (DI) on survival in patients receiving ifosfamide-based salvage therapy [abstract]. Proc Amer Soc Clin Oncol 1993; 12: 233. 27 SAS/STAT User's Guide, Vol. 2, Version 6, 4th Ed. 28 Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitmore W, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43: 3403– 7. 29 Motzer RJ, Geller NL, Tan C, Herr H, Morse M, Fair W, et al. Salvage chemotherapy for patients with germ cell tumors, the Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 1991; 67: 1305– 10. 30 Horwich A, A'Heran R, Gildersleve J, Dearnaley DP. Prognostic factor analysis of conventional dose salvage therapy of patients with metastatic non seminomatous germ cell cancer [abstract]. Proc Amer Soc Clin Oncol 1993; 12: 232. 31 Droz JP, Kramar A, Nichols C, Schmoll H, Auperin A, Harsdick A, et al. Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: assignment of prognostic groups [abstract]. Proc Amer Soc Clin Oncol 1993; 12: 229. 32 Murphy BA, Motzer RJ, Bosl GJ. Phase II study of Iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors: the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs 1992; 10: 327– 30. Citing Literature Volume73, Issue1015 May 1994Pages 2520-2526 ReferencesRelatedInformation